arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CANNAPHARMARX, INC.

CPMD
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Neutral
auto_awesome

Analytical Summary

CANNAPHARMARX, INC. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap
Dividend Yield
Revenue Growth 87.1%
Op. Margin -108.7%
ROIC 1.8%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$627.46K
↑ +87.1%
Net Income Profit after all expenses
$-382.02K
↑ +44.7%
Operating Margin Operating profit as % of sales
-108.7%
↑ +23.7% 0th
FCF / Share Free cash flow per share
$-0.00
↓ -48.4%
Long-Term Debt Long-term obligations
$7.00M
↓ -0.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
95
Financial Health
43
Cash Quality
25

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 62 quarters